New Therapeutic Targets for Mood Disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. These include: (1) glycogen synthase kinase-3 (GSK-3) and protein kinase C (PKC), (2) the purinergic system, (3) histone deacetylases (HDACs), (4) the melatonergic system, (5) the tachykinin neuropeptides system, (6) the glutamatergic system, and (7) oxidative stress and bioenergetics. The paper reviews data on new compounds that have shown antimanic or antidepressant effects in subjects with mood disorders, or similar effects in preclinical animal models. Overall, an improved understanding of the neurobiological underpinnings of mood disorders is critical in order to develop targeted treatments that are more effective, act more rapidly, and are better tolerated than currently available therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“Mood disorders, such as bipolar disorder (BPD) and major depressive disorder (MDD), are severe, chronic, and disabling psychiatric disorders commonly associated with persistent subsyndromal symptoms and frequent episode relapses[1].”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationThe Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Notably, the mood stabilizer valproate is an HDAC inhibitor, suggesting that its effects at this target may play a therapeutic role in mood stabilization, although it may also be associated with side effects such as teratogenicity or polycystic ovarian syndrome[60,61].”
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationOxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 1×
“Increasing evidence suggests that oxidative stress parameters play a key role in the pathophysiology of BPD[121,122].”
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“For instance, less than one-third of patients with MDD achieve remission after 10–14 weeks of treatment with a standard antidepressant[2].”
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“For instance, the NMDA antagonists dizocilpine (MK-801) and CGP 37849 exert significant antidepressant-like effects alone or combined with standard antidepressants[74,92,93,94,95].”
Antidepressant Actions of Histone Deacetylase Inhibitors
Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., Wu, E. Y., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1758-09.2009 · Cited by 624 · cited 1×
“Recently, the use of two HDAC inhibitors (two selective inhibitors of class I and II HDACs) administered directly into the nucleus accumbens induced potent antidepressant-like effects in several behavioral models; furthermore, these effects were seen at the gene expression level[59].”
Antidepressant-Like Effects of the Histone Deacetylase Inhibitor, Sodium Butyrate, in the Mouse
Schroeder, F. A., Lin, C. L., Crusio, W. E., & Akbarian, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.036 · Cited by 541 · cited 1×
“Two other preclinical studies[57,58] described antidepressant-like effects associated with sodium butyrate, a nonspecific class I and II HDAC inhibitor.”
Oxidative stress markers in bipolar disorder: A meta-analysis
Andreazza, A. C., Kauer-Sant'Anna, M., Frey, B. N., Bond, D. J., Kapczinski, F., Young, L. T., & Yatham, L. N. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.013 · Cited by 526
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder
Kuloglu, M., Ustundag, B., Atmaca, M., Canatan, H., Tezcan, A. E., & Cinkilinc, N. (2002) · Cell Biochemistry and Function · doi:10.1002/cbf.940 · Cited by 321 · cited 1×
“Altered levels of glutathione, the most abundant antioxidant substrate in all tissues, have been described in BPD subjects[123,124].”
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis
Banasr, M., Soumier, A., Hery, M., Mocaër, E., & Daszuta, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.025 · Cited by 318 · cited 1×
“Agomelatine is also known to increase both norepinephrine and dopamine, and to increase cell proliferation and neurogenesis in the ventral dentate gyrus[66,78].”
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · cited 1×
“However, the efficacy of MK869 was not subsequently replicated in a multisite, placebo-controlled, phase III trial[83].”
Lucae, S., Salyakina, D., Barden, N., Harvey, M., Gagné, B., Labbé, M., Binder, E. B., Uhr, M., Paez-Pereda, M., Sillaber, I., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl166 · Cited by 261
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.43 · Cited by 213 · cited 3×
“These initial results were confirmed in two recent, 3-week, double-blind, placebo-controlled, monotherapy studies[30,31].”
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
Zarate, C. A., Singh, J. B., Carlson, P. J., Quiroz, J., Jolkovsky, L., Luckenbaugh, D. A., & Manji, H. K. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00530.x · Cited by 208 · cited 3×
“The study by Zarate and colleagues tested higher doses of up to 140 mg/day and ratings were obtained daily during the first week, thus permitting the assessment of early antimanic effects[31].”
Self-citationMachado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195 · cited 1×
“Novel treatments are expected to address these clinical challenges, and it is critical to the health of our patients that the next generation of treatments for mood disorders be more effective, better tolerated, and act faster than currently available treatments[7].”
Self-citationShaltiel, G., Maeng, S., Malkesman, O., Pearson, B., Schloesser, R. J., Tragon, T., Rogawski, M., Gasior, M., Luckenbaugh, D., Chen, G., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.20 · Cited by 173
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171 · cited 2×
“In neuronal tissue, HDAC inhibitors limit histone deacetylation mostly by inactivating class I or II HDACs, thus increasing histone acetylation (for a review see Grayson et al.[55]).”
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171 · cited 2×
“Therefore, diverse glutamatergic modulators that target both ionotropic and metabotropic glutamate receptors have been tested in „„proof of concept‟‟ studies in mood disorders[89].”
Self-citationMizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 1×
“Riluzole also enhances glutamate reuptake and activates synthesis of neurotrophins[109,110].”
Creatine monohydrate in resistant depression: A preliminary study
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00532.x · Cited by 118
Mallinger, A. G., Thase, M. E., Haskett, R., Buttenfield, J., Luckenbaugh, D. A., Frank, E., Kupfer, D. J., & Manji, H. K. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00636.x · Cited by 44
Cited by
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., et al. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/627375 · Cited by 687
Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications
Dwivedi, Y. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/ydwivedi · Cited by 169
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
“61,62 68 Some of these agents may prove to have beneficial effects on appetite or weight regulation, and ultimately therapeutic effects in patients with BED.”
Ketamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression
Bellet, M. M., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023982 · Cited by 70
Metadata
- Authors
- Machado-Vieira, R., Salvadore, G., DiazGranados, N., Ibrahim, L., Latov, D., Wheeler-Castillo, C., Baumann, J., Henter, I. D., & Zarate, C. A.
- Venue
- The Scientific World JOURNAL
- Publisher
- Wiley
- Published
- 2010
- Volume
- 10
- Pages
- 713-726
- ISSN
- 1537-744X (ISSN-L)
- OpenAlex
- W2009939501
- Cited by
- 63
- References
- 31
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.